Immunovaccine Inc. (IMV) announced Wednesday that early studies of three recombinant protective antigen (rPA) single-dose vaccines have been shown to protect animal models against anthrax infection.
The National Institutes of Health (NIH) is leading the study, which involved giving a single dose of the vaccine to rabbits. After 28 days, the subjects were put in contact with lethal amounts of anthrax bacterial spores. Fifteen of 24 subjects were protected against infection.
According to the announcement, those animals that succumbed to the bacteria were in the control group that was given a placebo.
"This study shows that DepoVax is compatible with multiple sources of rPA and can enable a single-dose, rapid-response anthrax vaccine," IMV CEO Marc Mansour said. "We will be working to establish a path with an rPA provider to advance a DepoVax/rPA vaccine towards Phase I human clinical trials."
This study also helped to determine the potency of vaccines that have been developed by the company.
Currently there is a multiple-dose vaccine, BioThrax, that has been approved by the Food and Drug Administration to protect against anthrax spore infection.